To permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so.
About This Bill
Committee
Latest Action · September 21, 2023
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.